Mesothelioma is a rare and aggressive cancer mainly caused by asbestos exposure that creates challenges for patients and caregivers. Immune checkpoint inhibitors have brought hope to patients, but new data from Australia is raising questions about their safety and effectiveness. In order to make informed decisions, patients must understand all[…]
Full Archive
Multimodal Therapy to Treat Pleural Mesothelioma
Malignant pleural mesothelioma is a deadly cancer that is mainly caused by asbestos exposure. It affects the lungs’ lining. It is a very hard to treat cancer because it is very aggressive and is often diagnosed at a late stage. New surgical and therapeutic methods are offering hope though. A[…]
Prospective Data Collection Initiative on Thoracic Malignancies (DuTOC)
Primary Outcome Measures Progression free survival Secondary outcome Measures Disease free survival Overall survival Health related quality of life Inclusion Criteria Age ≥ 18 years; Histo/cytopathological proof of a thoracic malignancy, or a strong suspicion (after imaging and multidisciplinary board); Informed consent for longitudinal observational data collection; Exclusion Criteria Mentally[…]
Gene Expression’s Relationship with Pleural Mesothelioma
Alterations in DNA of patients exposed to asbestos can lead to gene expression, which explains the development of malignant pleural mesothelioma, a rare and aggressive cancer. Scientists were able to analyze public RNA-seq data through a comprehensive bioinformatics pipeline. This led to researchers being able to develop a view of[…]
CRS and HIPEC for Peritoneal Mesothelioma
Peritoneal mesothelioma is a rare and aggressive cancer linked to asbestos exposure. A promising option for treating the cancer includes cytoreductive surgery (CRS) with heated chemotherapy (HIPEC). A new article explains cytoreductive surgery and HIPEC for the treatment of peritoneal mesothelioma. Cytoreductive surgery removes as many tumors as possible. In[…]
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)
Primary Outcome Measures Overall Survival Secondary Outcome Measures Progression Free Survival Best Response: Objective Response Rate (ORR) Best Response: Disease Control Rate (DCR) Best Response: Clinical Benefit Rate (CBR) Other Outcome Measures Survival Rate at 12 Months Survival Rate at 18 Months Survival Rate at 24 Months Survival Rate at[…]
Analysis of 70 Mesothelioma Cases
Malignant pleural mesothelioma is a severe cancer mainly caused by asbestos exposure. It often appears decades after exposure. Early on, symptoms can be unclear, making it difficult to diagnose. Even though the cancer is rare, a mesothelioma diagnosis is still concerning since there is a lack of treatment options. An[…]
PORT-7 for the Treatment of Mesothelioma
Results from a clinical trial being performed on malignant pleural mesothelioma patients will be presented at the American Association for Cancer Research meeting being held in Chicago, Illinois. Results will be posted by internationally known mesothelioma expert Dr. Luciano Mutti of the department of Applied Clinical Sciences and Biotechnology at[…]
First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis. (FLAT)
Primary Outcome Measures Time to Diagnosis Hospitalization time Secondary Outcome Measures Patient’s discomfort/pain Complications Rate of Non Specific Pleuritis Inclusion Criteria Undiagnosed pleural effusion with the character of a lymphocytic exudate Exclusion Criteria Empyema Transudate pleural effusion. Central airway obstruction by tumor. Existence of extensive adhesions that do not allow[…]
Ageing and Mesothelioma
Mesothelioma, a rare and aggressive cancer mainly caused by asbestos exposure, mostly affects the lining of the lungs, but can also affect the lining of the abdomen, heart, and testicles. Older adults are mostly at risk, especially those who worked with asbestos. A new article from the Australasian Journal on[…]
